Inari Medical Announces PEERLESS Data to be Presented During Final Clinical Trial Sessions at TCT 2024

IRVINE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that data from the PEERLESS study will be presented by Dr. Wissam Jaber, Professor of Medicine at Emory University School of Medicine, during the Late-Breaking Clinical Trial Sessions at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. The presentation will take place on October 29^and.

The PEERLESS study is a prospective, randomized controlled trial (“RCT”) comparing outcomes in patients with intermediate-risk pulmonary embolism (“PE”) treated with the FlowTriever system versus catheter-directed thrombolysis. The primary endpoint is a win-rate analysis of key clinical and hospital resource utilization outcomes. This study will provide clinicians with critical information regarding the optimal treatment for PE patients.